ARK™ Voriconazole II Assay

The ARK™ Voriconazole II Assay is a highly specific homogeneous enzyme immunoassay for the therapeutic drug monitoring of Voriconazole in human serum or plasma. The assay provides excellent precision at very low concentrations, an essential quality in the long-term monitoring of patients.

Because of its ability to measure trough voriconazole levels with high accuracy and fast turn-around time, the assay is a useful method for Therapeutic Drug Monitoring of voriconazole, without any cross-reactivity to the primary metabolite Voriconazole-N-Oxide.

Assay Characteristics

  • Excellent precision even at very low concentrations
  • Trough level measurement with high accuracy
  • No cross-reactivity to the major metabolite Voriconazole-N-oxide
  • Liquid, stable, ready-to-use reagents, calibrators and controls
  • Application protocols for all major clinical chemistry analyzers


Voriconazole is a broad-spectrum, second generation triazole antifungal agent. It is currently considered to be the drug of choice for the treatment of invasive aspergillosis, candidiasis and other serious mycoses, a major cause of life-threatening infections in immune-compromised patients.

The drug is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine. Due to its high inter- and intra-individual pharmacokinetics, it is crucial to monitor serum levels to ensure optimal patient treatment. In addition, voriconazole pharmacokinetics are non-linear, which is why dose increases may lead to disproportionately higher drug exposure. There are also a substantial number of drug-drug interactions that may either reduce or increase the effective exposure of voriconazole. As a consequence, it is extremely difficult to produce predictable trough concentrations.